| Literature DB >> 25659141 |
Flávio V Loures1, Marc Röhm2, Chrono K Lee3, Evelyn Santos3, Jennifer P Wang3, Charles A Specht3, Vera L G Calich4, Constantin F Urban2, Stuart M Levitz3.
Abstract
Plasmacytoid dendritic cells (pDCs) were initially considered as critical for innate immunity to viruses. However, our group has shown that pDCs bind to and inhibit the growth of Aspergillus fumigatus hyphae and that depletion of pDCs renders mice hypersusceptible to experimental aspergillosis. In this study, we examined pDC receptors contributing to hyphal recognition and downstream events in pDCs stimulated by A. fumigatus hyphae. Our data show that Dectin-2, but not Dectin-1, participates in A. fumigatus hyphal recognition, TNF-α and IFN-α release, and antifungal activity. Moreover, Dectin-2 acts in cooperation with the FcRγ chain to trigger signaling responses. In addition, using confocal and electron microscopy we demonstrated that the interaction between pDCs and A. fumigatus induced the formation of pDC extracellular traps (pETs) containing DNA and citrullinated histone H3. These structures closely resembled those of neutrophil extracellular traps (NETs). The microarray analysis of the pDC transcriptome upon A. fumigatus infection also demonstrated up-regulated expression of genes associated with apoptosis as well as type I interferon-induced genes. Thus, human pDCs directly recognize A. fumigatus hyphae via Dectin-2; this interaction results in cytokine release and antifungal activity. Moreover, hyphal stimulation of pDCs triggers a distinct pattern of pDC gene expression and leads to pET formation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25659141 PMCID: PMC4450068 DOI: 10.1371/journal.ppat.1004643
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Fig 1A. fumigatus hyphae are recognized by the mannose receptor, Dectin-2, on pDCs.
Human pDCs were purified from PBMCs fractions using CD304-coated magnetic beads. (A) pDCs were treated with no inhibitors, dextran (1 mg/mL), mannan (1 mg/mL), laminarin (0.5 mg/mL) or mannan and laminarin for 30 minutes. The pDCs (5×104) were then incubated for 2 hr with A. fumigatus hyphae (5×104). The cell association was quantified by counting number of pDCs associated (touching or spreading over) with hyphae in 10 different fields. The percent cell association was calculated by dividing the number of pDC associated with hyphae by the total number of pDC counted and then multiplying by 100. (B) Same as in A except pDCs were treated with anti-Dectin-1 (100 μg/mL) and anti-Dectin-2 (100 μg/mL) antibodies for 30 minutes prior to incubation with hyphae. Data represent means ± SE of % cell association from three donors. *P<0.05. (C) Representative photomicrographs of pDCs incubated with A. fumigatus hyphae under the conditions described in panel B.
Fig 2Dectin-2 is involved in antifungal activity and cytokine release by pDCs stimulated with A. fumigatus hyphae.
(A) Human pDCs were isolated from PBMCs using magnetic beads. The pDCs (5 × 104) were incubated with A. fumigatus hyphae (5 × 103) for 2 hr in the presence or absence of anti-Dectin-2 antibody. Antifungal activity of pDCs was then measured by the XTT assay. Data represent means ± SE from three donors, each tested in triplicate. *P = 0.004. (B-C) A. fumigatus conidia (5 × 104) were plated in 96-well plates and grown in pDC media to hyphae. pDCs (5 × 104) were left untreated or incubated with anti-Dectin-2 (100 μg/mL) or anti-Dectin-1 (100 μg/mL) antibodies and then added to the hyphae. Control wells contained pDCs only, pDCs and antibodies, or pDC and CpG (10 μg/mL). After 6 hr, the supernatants were removed and analyzed by ELISA for TNF-α (B) and IFN-α (C). Data represent means ± SE of cytokine concentrations from two (IFN-α) or three (TNF-α) pDC donors, each tested in triplicate. *P<0.05 comparing cytokine secretion by A. fumigatus-stimulated pDCs with A. fumigatus-stimulated pDCs treated with anti-Dectin-2 antibody.
Fig 3A. fumigatus hyphae trigger signaling responses by Dectin-2 and FcRγ cooperation.
B3Z cells (2 × 105) containing a reporter plasmid for NFAT coupled to the β-galactosidase gene were transduced with WT FcRγ chain, Dectin-2, Dectin-2 and a signaling-deficient mutant of FcRγ chain Dectin-2 and WT FcRγ chain. Cells were either left unstimulated or stimulated with A. fumigatus hyphae (1 × 105), A. fumigatus conidia (1 × 105) or zymosan (100 μg/ml). Fluorescence intensity, a reflection of NFAT activity, was measured at 5 min intervals for 1 hr. Data are means of RFU/min ± SD of duplicate wells and are representative of two independent experiments. * P<0.05.
Fig 4Detection of pDC extracellular traps (pETs) by immunofluorescence.
Human pDCs (2 × 105/well) were left unstimulated (Unstim) or stimulated for 4 hr with A. fumigatus hyphae (2 × 105). pDCs associated with A. fumigatus hyphae showed evidence of ETosis. pETs were visualized by indirect immunofluorescence using primary antibodies against citrullinated histone H3 and the pDC marker CD123. Alexa Fluor 488- and 568-conjugated secondary antibodies were used for visualization of citrullinated histone H3 (green channel) and CD123 (red channel), respectively. DNA was stained with DAPI. Images were captured with a confocal microscope and a 60x oil immersion objective. Wavelengths of 405 nm (diode), 488 nm (Argon), and 543 nm (HeNe) were used to excite DAPI, Alexa Fluor 488 (and transmission images), and Alexa Fluor 568, respectively. Images were captured in separate passes to avoid cross talk and are presented as maximum intensity projections from Z-stacks. (A) Unstimulated pDCs. (B-D) Aspergillus-stimulated pDCs demonstrating pETs formation. The data are representative of three independent experiments.
Fig 5Scanning electron microscopy of pDCs incubated with A. fumigatus hyphae.
Human pDCs (2 × 105/well) were stimulated for 4 hr with A. fumigatus hyphae (4 × 105). The samples were then fixed and imaged by scanning electron microscopy. Areas with pETs are shown at low (left panels) and high (right panels) magnification. The data are representative of two independent experiments.
Fig 6The pDC transcriptome following stimulation with A. fumigatus.
Human pDCs (2 × 105) were left unstimulated or stimulated for 2 or 4 hr with A. fumigatus (Af) hyphae (2 × 105). As a positive control, pDCs were stimulated with CpG (20 μg/mL) for 4 hr. The RNA was extracted, converted into cDNA, amplified, labeled, hybridized to microarrays, and analyzed as described in Methods. (A, B) Venn diagrams showing the number of up-regulated and down-regulated genes found in each experimental group as well as the overlap between groups. (C, D) Regulated genes classified in categories according to the NetAffx program. (E) A heat map of the 250 genes (see S1 Table) differentially expressed following hyphal or CpG stimulation. Each column represents microarray data from an individual donor’s pDCs that were left unstimulated (number 1, orange columns), Aspergillus-infected for 2 hr (number 2, green columns), Aspergillus-infected for 4 hr (number 3, yellow columns) or CpG-stimulated for 4 hr (number 4, blue columns). The dendrogram above the heat map was generated using Transcriptome Analysis Console Software (TAC) and conveys similarities among pDC samples. Numbers provided with the color spectrum below the heat map are indicative of the linear fold change of each gene. The data are from three donors.
Dendritic cell activation.
| Gene Symbol | Gene description | Fold change | ||
|---|---|---|---|---|
| Asp 2h | Asp 4h | CpG | ||
|
|
| |||
| CLECL1 | C-type lectin-like 1 | 1.78 ± 0.80 |
|
|
| TLR7 | Toll-like receptor 7 | 2.82 ± 0.51 |
| 4.19 ± 1.02 |
| CLEC2D | C-type lectin domain family 2, member D | -1.26 ± 0.43 |
|
|
| CD180 | CD180 molecule | -1.74 ± 0.98 |
| 1.15 ± 0.25 |
| CLEC6A- | C-type lectin domain family 6, member A | -1.29 ± 0.28 |
| 1.66 ± 1.48 |
| CLEC12A | C-type lectin-like 1 |
|
| 1.24 ± 1.56 |
| CLEC4C | C-type lectin domain family 4, member C | 1.30 ± 0.67 |
| -2.81 ± 0.62 |
| C5AR1 | Complement component 5a receptor 1 | -2.70 ± 0.17 |
| -2.45 ± 0.81 |
|
| ||||
| STAT4 | Signal transducer and activator of transcription 4 | 1.67 ± 0.52 |
|
|
| STAT2 | Signal transducer and activator of transcription 2 | 1.25 ± 0.44 |
|
|
| IL6ST | Interleukin 6 signal transducer | 1.11 ± 0.75 |
| 1.89 ± 0.49 |
| STAT1 | Signal transducer and activator of transcription 1 | -1.15 ± 0.14 |
|
|
| MAPKAPK3 | mitogen-activated prot kinase-actv prot kinase 3 | -1.38 ± 0.36 |
| -1.71 ± 0.45 |
|
|
| |||
| CXCL10 | Chemokine (C-X-C motif) ligand 10 | -1.39 ± 0.97 |
|
|
| IL2RA | Interleukin 2 receptor, alpha | 1.34 ± 0.48 |
|
|
| TNFSF4 | Tumor necrosis fact (ligand) superfam 4 |
|
|
|
| CXCL9 | Chemokine (C-X-C motif) ligand 9 | -1.81 ± 0.97 |
|
|
| TNFSF10 | Tumor necrosis fact (ligand) superfam 10 | -1.00 ± 0.05 |
|
|
| IL18RAP | Interleukin 18 receptor accessory protein | 1.41 ± 0.60 |
|
|
| CCL22 | Chemokine (C-C motif) ligand 22 | -1.33 ± 0.23 |
| 1.30 ± 0.21 |
| CCR7 | Chemokine (C-C motif) receptor 7 | 1.19 ± 0.26 |
|
|
| IL13 | Interleukin 13 | 1.42 ± 0.28 |
| 1.22 ± 0.81 |
| CCL20 | Chemokine (C-C motif) ligand 20 | -1.41 ± 0.39 |
| 1.25 ± 0.88 |
| CXCL3 | Chemokine (C-X-C motif) ligand 3 | -2.44 ± 0.76 |
| 1.06 ± 0.73 |
|
|
| |||
| SEC61B | Sec61 beta subunit |
|
| 2.33 ± 0.04 |
| LAMP3 | lysosomal-associated membrane protein 3 | -1.37 ± 0.42 |
|
|
| LOC100509457 | major histoc complex, class II, DQ alpha 1 | 1.45 ± 1.15 |
| 1.11 ± 1.10 |
| TAP1 | transporter 1, ATP-binding cassette, sub-family B | 1.10 ± 0.25 |
|
|
| TAP2 | transporter 2, ATP-binding cassette, sub-family B | -1.1 2± 0.33 |
| 1.52 ± 0.23 |
|
|
| |||
| SLC7A11 | solute carrier family 7, member 11 | 1.94 ± 0.82 |
|
|
| CDH1 | cadherin 1, type 1, E-cadherin (epithelial) | 1.32 ± 0.51 |
| 1.68 ± 0.43 |
| HAPLN3 | hyaluronan and proteoglycan link protein 3 | 1.05 ± 0.39 |
|
|
| FSCN1 | fascin homolog 1, actin-bundling protein | -1.36 ± 0.55 |
|
|
| STAP1 | signal transducing adaptor family member 1 | 1.58 ± 0.88 |
|
|
| SDK2 | sidekick cell adhesion molecule 2 | -1.27 ± 0.26 |
| 1.30 ± 0.26 |
| VAV2 | vav 2 guanine nucleotide exchange factor | -1.20 ± 0.95 |
| 1.91 ± 0.32 |
| SCYL3 | SCY1-like 3 (S. cerevisiae) | -1.15 ± 0.43 |
|
|
| FMNL3 | formin-like 3 | 1.17 ± 0.79 |
| 1.32 ± 0.07 |
| PEAK1 | NKF3 kinase family member | -1.11 ± 0.55 |
|
|
| B4GALT1 | UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase | 1.05 ± 0.37 |
| -1.57 ± 0.03 |
| VAV3 | vav 3 guanine nucleotide exchange factor | 1.33 ± 0.65 |
| -1.86 ± 0.57 |
| VCAN | versican | -2.90 ± 1.18 |
| -6.44 ± 1.00 |
* Significant (P<0.05) changes are shown in bold.
Human pDCs were left unstimulated or stimulated with A. fumigatus hyphae for 2 hr (Asp 2h), A. fumigatus hyphae for 4 hr (Asp 4h), or with CpG for 4 hr (CpG) and then analyzed for gene expression by microarray as in Methods. Genes putatively involved in dendritic cell functions (such as innate immune receptors, signaling, cytokine and chemokine production, MHC and cell activation involved genes, and genes involved and migration and adhesion) that had significant changes in the Asp 4 hr group are shown and compared with the other stimulated groups. Data are expressed as fold change compared to unstimulated pDCs and represent the mean ± SD of three donors (except for the CpG group where the data represent the mean of 2 donors).
Genes encoding type I interferons.
| Gene Symbol | Gene description | Fold change | ||
|---|---|---|---|---|
| Asp 2h | Asp 4h | CpG | ||
|
| ||||
| IFNA7 | interferon, alpha 7 |
|
|
|
| IFNA21 | interferon, alpha 21 |
|
|
|
| IFNA4 | interferon, alpha 4 |
|
|
|
| IFNA10 | interferon, alpha 10 |
|
|
|
| IFNA17 | interferon, alpha 17 |
|
|
|
| IFNA1 | interferon, alpha 1 |
|
|
|
| IFNA8 | interferon, alpha 8 |
|
|
|
| IFNA13 | interferon, alpha 13 |
|
|
|
| IFNA2 | interferon, alpha 2 |
|
|
|
| IFNA16 | interferon, alpha 16 |
|
|
|
| IFNA5 | interferon, alpha 5 |
|
|
|
| IFNW1 | interferon, omega 1 |
|
|
|
| IFNB1 | interferon, beta 1 |
|
|
|
| IFNE | interferon, epsilon |
|
|
|
| IFNA14 | interferon, alpha 14 |
|
|
|
* Significant (P<0.05) changes are shown in bold.
As in Table 1 except genes encoding type I IFNs are shown.
Type I Interferon-induced genes.
| Gene Symbol | Gene description | Fold change | ||
|---|---|---|---|---|
| Asp 2h | Asp 4h | CpG | ||
|
| ||||
| IFI44L | interferon-induced protein 44-like | 1.34 ± 0.26 |
|
|
| USP18 | ubiquitin specific peptidase 18 | -1.09 ± 0.20 |
|
|
| SAMD9L | sterile alpha motif domain containing 9-like | -1.32 ± 0.47 |
|
|
| OAS2 | 2′-5′-oligoadenylate synthetase 2, 69/71kDa | -1.15 ± 0.12 |
|
|
| XAF1 | XIAP associated factor 1 | -1.31 ± 0.17 |
|
|
| EIF2AK2 | eukaryotic translation initiation factor 2-alpha kinase | 1.05 ± 1.06 |
|
|
| EBI3 | Epstein-Barr virus induced 3 | -1.02 ± 0.67 |
|
|
| HERC5 | HECT and RLD domain containing E3 ubiquitin protein ligase 5 | 1.17 ± 0.72 |
|
|
| STAMBPL1 | STAM binding protein-like 1 | 1.21 ± 0.62 |
|
|
| IFIT1 | interferon-induced protein with tetratricopeptide repeats 1 | -2.07 ± 0.16 |
|
|
| IFI16 | interferon, gamma-inducible protein 16 | 1.55 ± 0.35 |
|
|
| OAS3 | 2′-5′-oligoadenylate synthetase 3, 100kDa | -2.06 ± 0.47 |
|
|
| OAS1 | 2′-5′-oligoadenylate synthetase 1, 40/46kDa | 1.06 ± 0.10 |
|
|
| IFI6 | interferon, alpha-inducible protein 6 | 1.02 ± 0.52 |
|
|
| PML | promyelocytic leukemia | -1.24 ± 0.51 |
|
|
| RSAD2 | radical S-adenosyl methionine domain cont. 2 | -1.43 ± 0.06 |
|
|
| DDX60 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 | -1.63 ± 0.81 |
|
|
| IRF2 | interferon regulatory factor 2 | -1.12 ± 0.50 |
|
|
| IFI44 | interferon-induced protein 44 | -1.70 ± 0.45 |
|
|
| SP100 | SP100 nuclear antigen | -1.15 ± 0.47 |
|
|
| ADAR | adenosine deaminase, RNA-specific | 1.16 ± 0.19 |
|
|
| DHX58 | DEXH (Asp-Glu-X-His) box polypeptide 58 | -1.23 ± 0.30 |
|
|
| IFI35 | interferon-induced protein 35 | -1.11 ± 0.51 |
|
|
| MX1 | Myxovirus resistance 1, ifn-inducible protein p78 | 1.10 ± 0.31 |
|
|
| IFIT5 | ifn-induced protein tetratricopeptide repeats 5 | -1.29 ± 0.21 |
|
|
*Genes previously described as regulated in viral infection.
Significant (P<0.05) changes are shown in bold.
As in Table 1 except type I IFN-induced genes are shown.
Apoptosis and regulation.
| Gene Symbol | Gene description | Fold change | ||
|---|---|---|---|---|
| Asp 2h | Asp 4h | CpG | ||
|
| ||||
| CD38 | CD38 molecule | 1.07 ± 0.55 |
|
|
| BCL2L1 | BCL2-like 1 | -1.22 ± 0.56 |
|
|
| ARHGEF17 | Rho guanine nucleotide exchange factor (GEF) 17 | 1.06 ± 0.04 |
| 1.08 ± 0.05 |
| MLLT11 | myeloid/lymphoid or mixed-lineage leukemia | 1.54 ± 0.40 |
|
|
| FAS | Fas (TNF receptor superfamily, member 6) | -1.12 ± 0.25 |
| 1.46 ± 0.53 |
| ARHGEF3 | Rho guanine nucleotide exchange factor (GEF) 3 | 1.40 ± 0.53 |
|
|
| ANXA1 | annexin A1 | -1.20 ± 0.03 |
| 1.12 ± 0.25 |
| CEBPB | CCAAT/enhancer binding protein (C/EBP), beta | -1.47 ± 0.26 |
| -1.17 ± 0.42 |
| SOX4 | SRY (sex determining region Y)-box 4 | 1.92 ± 1.13 |
| -1.97 ± 0.13 |
| JMY | junction mediating and regulatory protein, p53 | -1.21 ± 0.46 |
| -2.10 ± 0.06 |
| TNFSF14 | TNF (ligand) superfamily, member 14 | -2.07 ± 0.50 |
| -1.24 ± 0.81 |
|
| ||||
| CALCRL | calcitonin receptor-like | 1.15 ± 1.09 |
|
|
| TRAFD1 | TRAF-type zinc finger domain containing 1 | 1.48 ± 0.14 |
|
|
| FCRL3 | Fc receptor-like 3 | -1.12 ± 1.03 |
| 1.75 ± 0.43 |
| ENDOG | endonuclease G | 1.12 ± 0.36 |
| 1.49 ± 0.17 |
| CD200 | CD200 molecule | -1.67 ± 0.76 |
| 3.20 ± 0.19 |
* Significant (P<0.05) changes are shown in bold.
As in Table 1, except genes associated with apoptosis and regulation are shown.